Microbot Medical “announces that it has received the FDA approval to proceed with its pivotal human clinical trial as part of its Investigational Device Exemption application for its LIBERTY Endovascular Robotic Surgical System. The study will be conducted in the U.S., and the Company has already signed a clinical trial service agreement with a leading academic medical center. The Company is also in the process of engaging additional leading centers to participate in the trial. In parallel to commencing the pivotal human clinical trial, the Company is completing its biocompatibility tests as required by its IDE application.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
- Microbot Medical’s LIBERTY System Success with Corewell Health
- Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
- Microbot Medical announces results from first phase of collab with Cornell
- Microbot Medical Outlines Regulatory Goals and Investor Cautions